Manipulating mitochondrial electron flow enhances tumor immunogenicity.


Journal

Science (New York, N.Y.)
ISSN: 1095-9203
Titre abrégé: Science
Pays: United States
ID NLM: 0404511

Informations de publication

Date de publication:
22 09 2023
Historique:
medline: 25 9 2023
pubmed: 21 9 2023
entrez: 21 9 2023
Statut: ppublish

Résumé

Although tumor growth requires the mitochondrial electron transport chain (ETC), the relative contribution of complex I (CI) and complex II (CII), the gatekeepers for initiating electron flow, remains unclear. In this work, we report that the loss of CII, but not that of CI, reduces melanoma tumor growth by increasing antigen presentation and T cell-mediated killing. This is driven by succinate-mediated transcriptional and epigenetic activation of major histocompatibility complex-antigen processing and presentation (MHC-APP) genes independent of interferon signaling. Furthermore, knockout of methylation-controlled J protein (MCJ), to promote electron entry preferentially through CI, provides proof of concept of ETC rewiring to achieve antitumor responses without side effects associated with an overall reduction in mitochondrial respiration in noncancer cells. Our results may hold therapeutic potential for tumors that have reduced MHC-APP expression, a common mechanism of cancer immunoevasion.

Identifiants

pubmed: 37733872
doi: 10.1126/science.abq1053
doi:

Substances chimiques

Antigens, Neoplasm 0
DNAJC15 protein, human 0
Electron Transport Complex I EC 7.1.1.2
Electron Transport Complex II EC 1.3.5.1
Histones 0
HSP40 Heat-Shock Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1316-1323

Commentaires et corrections

Type : CommentIn

Auteurs

Kailash Chandra Mangalhara (KC)

Salk Institute for Biological Studies, La Jolla, CA 92037, USA.

Siva Karthik Varanasi (SK)

Salk Institute for Biological Studies, La Jolla, CA 92037, USA.

Melissa A Johnson (MA)

Salk Institute for Biological Studies, La Jolla, CA 92037, USA.

Mannix J Burns (MJ)

Salk Institute for Biological Studies, La Jolla, CA 92037, USA.

Gladys R Rojas (GR)

Salk Institute for Biological Studies, La Jolla, CA 92037, USA.

Pau B Esparza Moltó (PB)

Salk Institute for Biological Studies, La Jolla, CA 92037, USA.

Alva G Sainz (AG)

Salk Institute for Biological Studies, La Jolla, CA 92037, USA.
Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, USA.

Nimesha Tadepalle (N)

Salk Institute for Biological Studies, La Jolla, CA 92037, USA.

Keene L Abbott (KL)

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Gaurav Mendiratta (G)

Salk Institute for Biological Studies, La Jolla, CA 92037, USA.

Dan Chen (D)

Salk Institute for Biological Studies, La Jolla, CA 92037, USA.

Yagmur Farsakoglu (Y)

Salk Institute for Biological Studies, La Jolla, CA 92037, USA.

Tenzin Kunchok (T)

Whitehead Institute Metabolomics Core Facility, Cambridge, MA 02139, USA.

Filipe Araujo Hoffmann (FA)

Salk Institute for Biological Studies, La Jolla, CA 92037, USA.

Bianca Parisi (B)

Salk Institute for Biological Studies, La Jolla, CA 92037, USA.

Mercedes Rincon (M)

Department of Immunology and Microbiology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO 80045, USA.

Matthew G Vander Heiden (MG)

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Marcus Bosenberg (M)

Departments of Pathology, Dermatology, and Immunology, Yale University School of Medicine, New Haven, CT 06520, USA.

Diana C Hargreaves (DC)

Salk Institute for Biological Studies, La Jolla, CA 92037, USA.

Susan M Kaech (SM)

Salk Institute for Biological Studies, La Jolla, CA 92037, USA.

Gerald S Shadel (GS)

Salk Institute for Biological Studies, La Jolla, CA 92037, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH